A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Clinical trial NCT03650452 · COMPLETED

Trial details

NCT number: NCT03650452
Sponsor: Takeda
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Epilepsy Dravet Syndrome Lennox-Gastaut Syndrome

Start date: 2018-08-08
Primary completion: 2020-06-09
Enrollment: 141

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.